Centessa Pharmaceuticals PLC Schedule 13G passive stakes

Pentwater Capital Management LP and Matthew Halbower have reported zero beneficial ownership of Centessa Pharmaceuticals plc's ordinary shares, signaling a complete divestment.

Index Ventures Life VI (Jersey) L.P., Yucca (Jersey) SLP, and Index Venture Life Associates VI Ltd have filed an amendment to Schedule 13G, confirming they beneficially own less than 5% of Centessa Pharmaceuticals' ordinary shares as of June 30, 2026.

Adage Capital Management, L.P. and associated individuals have filed a Schedule 13G, reporting their beneficial ownership of Centessa Pharmaceuticals plc.

Multiple Medicxi entities have filed a Schedule 13G amendment, reporting 0.0% beneficial ownership of Centessa Pharmaceuticals plc ordinary shares as of June 30, 2026.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G, reporting beneficial ownership of 1,800 shares of Centessa Pharmaceuticals PLC common stock as of June 30, 2026.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 7.39% of Centessa Pharmaceuticals plc's ordinary shares.

Adage Capital Management, L.P. and its associated individuals have reported beneficial ownership of 5.77% of Centessa Pharmaceuticals plc's ordinary shares as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 7.5% of Centessa Pharmaceuticals PLC's common stock as of March 31, 2026.

Avoro Capital Advisors LLC and Behzad Aghazadeh have disclosed a 9.97% beneficial ownership stake in Centessa Pharmaceuticals plc, holding 14,555,555 ordinary shares.

FMR LLC and Abigail P. Johnson have reported a 12.2% beneficial ownership stake in Centessa Pharmaceuticals PLC, holding 10,999,793 common shares.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 9.9% beneficial ownership stake in Centessa Pharmaceuticals PLC as of December 31, 2025.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a passive 8.06% beneficial ownership stake in Centessa Pharmaceuticals plc, holding 10,808,080 American Depositary Shares.

Adage Capital Management, L.P. and its principals reported a 7.48% beneficial ownership stake in Centessa Pharmaceuticals plc, totaling 10,035,000 ordinary shares.

FMR LLC and Abigail P. Johnson have reported a 7.0% beneficial ownership stake in Centessa Pharmaceuticals PLC, totaling 6,277,243 common shares.

Adage Capital Management, L.P. and its principals have disclosed a 6.29% beneficial ownership stake in Centessa Pharmaceuticals plc, holding 8,403,000 ordinary shares.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a 5.22% beneficial ownership stake in Centessa Pharmaceuticals plc, totaling 6,954,000 ordinary shares.